Serrapeptase After Liposuction for Lipedema: Limited Evidence for Antifibrotic Efficacy

Key Points

• Serrapeptase shows limited antifibrotic efficacy after liposuction for treating lipedema, which is concerning for clinical recommendations.
• The analysis indicates that patients undergoing liposuction for lipedema might not benefit from serrapeptase in reducing fibrosis or related complications.
• This observational analysis assessed outcomes involving serrapeptase and its impact on fibrosis in individuals with lipedema post-liposuction.
• The findings highlight the need for further research and caution regarding serrapeptase's recommended use in lipedema treatment.